KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival

Masato Terashima, Yoshihiko Fujita, Yosuke Togashi, Kazuko Sakai, Marco A. De Velasco, Shuta Tomida, Kazuto Nishio

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The KIAA1199 gene was first discovered to be associated with non-syndromic hearing loss. Recently, several reports have shown that the up-regulation of KIAA1199 is associated with cancer cell migration or invasion and a poor prognosis. These findings indicate that KIAA1199 may be a novel target for cancer therapy. Therefore, we explored in detail the function of KIAA1199 in cancer cells. In this study, we investigated the interaction of KIAA1199 protein with intracellular proteins in cancer cells. To this end, we expressed KIAA1199-MBP fusion protein and performed a pull-down assay. In addition, KIAA1199-overexpressing cancer cell lines were constructed using a retroviral vector and were used for further experiments. A pull-down analysis showed that the glycogen phosphorylase kinase ß-subunit (PHKB) interacted with the C-terminal region of KIAA1199 protein. Furthermore, we observed the interaction of KIAA1199 with glycogen phosphorylase brain form (PYGB) under serum-free conditions. The interaction promoted glycogen breakdown and cancer cell survival. Our findings indicate that KIAA1199 plays an important role in glycogen breakdown and cancer cell survival and that it may represent a novel target for cancer therapy.

Original languageEnglish
Pages (from-to)7040-7050
Number of pages11
JournalOncotarget
Volume5
Issue number16
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Phosphorylase Kinase
Glycogen
Cell Survival
Neoplasms
Proteins
Hearing Loss
Cell Movement
Up-Regulation
Cell Line

Keywords

  • Glycogen breakdown
  • Glycogen phosphorylase brain form
  • Glycogen phosphorylase kinase ß-subunit
  • KIAA1199

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Terashima, M., Fujita, Y., Togashi, Y., Sakai, K., De Velasco, M. A., Tomida, S., & Nishio, K. (2014). KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. Oncotarget, 5(16), 7040-7050.

KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. / Terashima, Masato; Fujita, Yoshihiko; Togashi, Yosuke; Sakai, Kazuko; De Velasco, Marco A.; Tomida, Shuta; Nishio, Kazuto.

In: Oncotarget, Vol. 5, No. 16, 2014, p. 7040-7050.

Research output: Contribution to journalArticle

Terashima, M, Fujita, Y, Togashi, Y, Sakai, K, De Velasco, MA, Tomida, S & Nishio, K 2014, 'KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival', Oncotarget, vol. 5, no. 16, pp. 7040-7050.
Terashima, Masato ; Fujita, Yoshihiko ; Togashi, Yosuke ; Sakai, Kazuko ; De Velasco, Marco A. ; Tomida, Shuta ; Nishio, Kazuto. / KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. In: Oncotarget. 2014 ; Vol. 5, No. 16. pp. 7040-7050.
@article{f080a1695b6d4adfb42d054abaf6a8dd,
title = "KIAA1199 interacts with glycogen phosphorylase kinase {\ss}-subunit (PHKB) to promote glycogen breakdown and cancer cell survival",
abstract = "The KIAA1199 gene was first discovered to be associated with non-syndromic hearing loss. Recently, several reports have shown that the up-regulation of KIAA1199 is associated with cancer cell migration or invasion and a poor prognosis. These findings indicate that KIAA1199 may be a novel target for cancer therapy. Therefore, we explored in detail the function of KIAA1199 in cancer cells. In this study, we investigated the interaction of KIAA1199 protein with intracellular proteins in cancer cells. To this end, we expressed KIAA1199-MBP fusion protein and performed a pull-down assay. In addition, KIAA1199-overexpressing cancer cell lines were constructed using a retroviral vector and were used for further experiments. A pull-down analysis showed that the glycogen phosphorylase kinase {\ss}-subunit (PHKB) interacted with the C-terminal region of KIAA1199 protein. Furthermore, we observed the interaction of KIAA1199 with glycogen phosphorylase brain form (PYGB) under serum-free conditions. The interaction promoted glycogen breakdown and cancer cell survival. Our findings indicate that KIAA1199 plays an important role in glycogen breakdown and cancer cell survival and that it may represent a novel target for cancer therapy.",
keywords = "Glycogen breakdown, Glycogen phosphorylase brain form, Glycogen phosphorylase kinase {\ss}-subunit, KIAA1199",
author = "Masato Terashima and Yoshihiko Fujita and Yosuke Togashi and Kazuko Sakai and {De Velasco}, {Marco A.} and Shuta Tomida and Kazuto Nishio",
year = "2014",
language = "English",
volume = "5",
pages = "7040--7050",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival

AU - Terashima, Masato

AU - Fujita, Yoshihiko

AU - Togashi, Yosuke

AU - Sakai, Kazuko

AU - De Velasco, Marco A.

AU - Tomida, Shuta

AU - Nishio, Kazuto

PY - 2014

Y1 - 2014

N2 - The KIAA1199 gene was first discovered to be associated with non-syndromic hearing loss. Recently, several reports have shown that the up-regulation of KIAA1199 is associated with cancer cell migration or invasion and a poor prognosis. These findings indicate that KIAA1199 may be a novel target for cancer therapy. Therefore, we explored in detail the function of KIAA1199 in cancer cells. In this study, we investigated the interaction of KIAA1199 protein with intracellular proteins in cancer cells. To this end, we expressed KIAA1199-MBP fusion protein and performed a pull-down assay. In addition, KIAA1199-overexpressing cancer cell lines were constructed using a retroviral vector and were used for further experiments. A pull-down analysis showed that the glycogen phosphorylase kinase ß-subunit (PHKB) interacted with the C-terminal region of KIAA1199 protein. Furthermore, we observed the interaction of KIAA1199 with glycogen phosphorylase brain form (PYGB) under serum-free conditions. The interaction promoted glycogen breakdown and cancer cell survival. Our findings indicate that KIAA1199 plays an important role in glycogen breakdown and cancer cell survival and that it may represent a novel target for cancer therapy.

AB - The KIAA1199 gene was first discovered to be associated with non-syndromic hearing loss. Recently, several reports have shown that the up-regulation of KIAA1199 is associated with cancer cell migration or invasion and a poor prognosis. These findings indicate that KIAA1199 may be a novel target for cancer therapy. Therefore, we explored in detail the function of KIAA1199 in cancer cells. In this study, we investigated the interaction of KIAA1199 protein with intracellular proteins in cancer cells. To this end, we expressed KIAA1199-MBP fusion protein and performed a pull-down assay. In addition, KIAA1199-overexpressing cancer cell lines were constructed using a retroviral vector and were used for further experiments. A pull-down analysis showed that the glycogen phosphorylase kinase ß-subunit (PHKB) interacted with the C-terminal region of KIAA1199 protein. Furthermore, we observed the interaction of KIAA1199 with glycogen phosphorylase brain form (PYGB) under serum-free conditions. The interaction promoted glycogen breakdown and cancer cell survival. Our findings indicate that KIAA1199 plays an important role in glycogen breakdown and cancer cell survival and that it may represent a novel target for cancer therapy.

KW - Glycogen breakdown

KW - Glycogen phosphorylase brain form

KW - Glycogen phosphorylase kinase ß-subunit

KW - KIAA1199

UR - http://www.scopus.com/inward/record.url?scp=84907081373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907081373&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 7040

EP - 7050

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -